It’s only fair to share… Nivegacetor CAS 2443487-67-8 MF C23H25F2N7O2 MW 469.5 g/mol (R)-7-(3,5-difluorophenoxy)-N-((1R,5S,8s)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine and (S)-7-(3,5-difluorophenoxy)-N-((1R,5S,8s)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine (7R)-7-(3,5-difluorophenoxy)-N-[(1S,5R)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine (7R)-7-(3,5-difluorophenoxy)-N-[(1R,5S,8s)-3-(6-methoxypyridazin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-6,7-dihydro5H-pyrrolo[1,2-b][1,2,4]triazol-2-aminegamma secretase modulator, SF4J7MVJ56, RG 6289, RG-6289, ROCHE, ALZHIEMER, Nivegacetor is a potent γ-secretase modulator. Nivegacetor is an investigational gamma-secretase modulator being developed by Roche for the treatment of Alzheimer’s disease.[1] The compound is also known by its development code name RG6289 and represents a second-generation gamma-secretase modulator designed to …